NASDAQ · Analyst Forecast

Nutriband Inc. (NTRB) Analyst Forecast

$6.22 NASDAQ: NTRB Market Cap $75.61M

Revenue and earnings estimates published by analysts covering Nutriband Inc. (NTRB), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Nutriband Inc., analysts forecast revenue rising from $2.20T in 2023 to $180.41T in 2028; the average estimate for 2028 earnings per share is $3.66; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2023	$2.20T	$2.20T	$2.20T	1
2024	$3.30T	$3.30T	$3.30T	1
2025	$2.30T	$2.30T	$2.30T	1
2026	$2.73T	$2.73T	$2.73T	1
2027	$95.41T	$95.41T	$95.41T	1
2028	$180.41T	$180.41T	$180.41T	1

Earnings per share forecast

Year	Low	Average	High	Analysts
2023	$-0.39	$-0.39	$-0.39	1
2024	$-0.23	$-0.23	$-0.23	1
2025	$-0.99	$-0.99	$-0.99	1
2026	$-6.20	$-6.20	$-6.20	1
2027	$1.57	$1.57	$1.57	1
2028	$3.66	$3.66	$3.66	1

Nutriband Inc. (NTRB) forecast — frequently asked questions

What are analysts forecasting for Nutriband Inc.'s earnings?

The average analyst estimate for Nutriband Inc. (NTRB) earnings per share in 2028 is 3.66, with individual estimates between 3.66 and 3.66.

How much revenue is Nutriband Inc. expected to make?

Analysts forecast Nutriband Inc. (NTRB) revenue of $180.41T in 2028, based on 1 published estimates.

How many analysts cover NTRB?

1 analyst contribute estimates for Nutriband Inc. (NTRB). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.